As of 2025-07-08, the EV/EBITDA ratio of Celldex Therapeutics Inc (CLDX) is -6.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CLDX's latest enterprise value is 1,443.44 mil USD. CLDX's TTM EBITDA according to its financial statements is -213.94 mil USD. Dividing these 2 quantities gives us the above CLDX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.8x - 13.6x | 13.2x |
| Forward P/E multiples | 15.0x - 20.6x | 17.8x |
| Fair Price | (48.08) - (43.57) | (49.69) |
| Upside | -318.5% - -298.0% | -325.9% |
| Date | EV/EBITDA |
| 2025-07-03 | -6.75 |
| 2025-07-02 | -6.78 |
| 2025-07-01 | -6.50 |
| 2025-06-30 | -6.23 |
| 2025-06-27 | -6.22 |
| 2025-06-26 | -6.49 |
| 2025-06-25 | -6.58 |
| 2025-06-24 | -6.64 |
| 2025-06-23 | -6.25 |
| 2025-06-20 | -6.28 |
| 2025-06-18 | -6.38 |
| 2025-06-17 | -6.14 |
| 2025-06-16 | -6.23 |
| 2025-06-13 | -6.52 |
| 2025-06-12 | -6.23 |
| 2025-06-11 | -6.26 |
| 2025-06-10 | -6.41 |
| 2025-06-09 | -6.35 |
| 2025-06-06 | -6.55 |
| 2025-06-05 | -5.98 |
| 2025-06-04 | -6.02 |
| 2025-06-03 | -6.09 |
| 2025-06-02 | -6.12 |
| 2025-05-30 | -6.06 |
| 2025-05-29 | -6.08 |
| 2025-05-28 | -5.71 |
| 2025-05-27 | -6.06 |
| 2025-05-23 | -6.23 |
| 2025-05-22 | -6.24 |
| 2025-05-21 | -6.11 |
| 2025-05-20 | -6.28 |
| 2025-05-19 | -6.41 |
| 2025-05-16 | -6.27 |
| 2025-05-15 | -6.16 |
| 2025-05-14 | -5.80 |
| 2025-05-13 | -6.01 |
| 2025-05-12 | -6.18 |
| 2025-05-09 | -5.61 |
| 2025-05-08 | -5.98 |
| 2025-05-07 | -5.79 |
| 2025-05-06 | -5.63 |
| 2025-05-05 | -6.22 |
| 2025-05-02 | -6.33 |
| 2025-05-01 | -6.35 |
| 2025-04-30 | -6.38 |
| 2025-04-29 | -6.41 |
| 2025-04-28 | -6.55 |
| 2025-04-25 | -5.99 |
| 2025-04-24 | -6.00 |
| 2025-04-23 | -5.95 |